



PRIOR AUTHORIZATION POLICY

- POLICY:** Oncology – Romvimza Prior Authorization Policy
- Romvimza™ (vimseltinib capsules – Deciphera/Ono Pharma)

REVIEW DATE: 02/19/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Romvimza, a kinase inhibitor, is indicated for the treatment of symptomatic **tenosynovial giant cell tumor (TGCT)** for which surgical resection will potentially cause worsening functional limitation or severe morbidity in adults.¹

Guidelines

Romvimza is not discussed in guidelines from the National Comprehensive Cancer Network (NCCN) yet. NCCN soft tissue sarcoma guidelines (version 4.2024 – November 21, 2024) recommend Turalio as a “preferred regimen” for the treatment of tenosynovial giant cell tumor/pigmented villonodular synovitis (category 1).² Other medications listed as “useful in certain circumstances” include imatinib and nilotinib (both category 2A).

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Romvimza. All approvals are provided for the duration noted below.

- **Romvimza™ (vimseltinib capsules – Deciphera/Ono Pharma) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

FDA-Approved Indication

1. Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).

Approve for 1 year if the patient meets BOTH of the following (A and B):

- A)** Patient is ≥ 18 years of age; AND
- B)** The tumor is not amenable to improvement with surgery.

CONDITIONS NOT COVERED

- **Romvimza™ (vimseltinib capsules – Deciphera/Ono Pharma) is(are) considered experimental, investigational or unproven for ANY other use(s); criteria will be updated as new published data are available.**

REFERENCES

1. Romvimza® capsules [prescribing information]. Waltham, MA: Deciphera; February 2025.
2. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (version 4.2024 – November 21, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed February 17, 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
New policy	--	02/19/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.